Momotaro-Gene Inc.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Momotaro-Gene is a clinical stage biotech company conducting two Phase IIa trials, localized prostate cancer and mesothelioma, in the US. We are a cancer gene therapy using REIC/Dkk-3 gene isolated and cloned at Okayama University, Japan. The adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) induces cancer-selective apoptosis and enhances anti-tumor immunity. Cancer selective apoptosis occurred due to ER stress and REIC protein induces the patients' own cancer CTL and also down-regulates T-regulatory cell.
One CRPC patient with lymph node metastases has been in complete remission for more than 7 years. This therapy is highly minimally invasive with only the fever at the night of injection.
Our next target is malignant mesothelioma, which does not have a good drug at all. Mouse model at Baylor College in the US showed great promise for the combination therapy with PD-1 inhibitor. Our P2 started last September and three patients has been treated so far.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
Ad-SGE-REIC
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Momotaro-Gene Inc.